cms.bioaccessla.com

Tag: first-in-human

  • Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil’s 2025 Clinical Research Rulebook: What Early-Stage Sponsors Should Do Differently

    Brazil continues to be one of the most important anchors for early-stage clinical development in Latin America, but the compliance baseline is moving. In 2026, Anvisa highlighted that Brazil’s clinical research environment has been updated through Law No. 14.874/2024 (ethical aspects of research with human beings) and the newer regulatory package RDC 945/2024 plus IN 338/2024 for clinical research supporting registration of medicines, which Anvisa notes took effect in early 2025 (Anvisa).

    For MedTech founders and regulatory directors planning first-in-human (FIH) or early pivotal work in the region, the strategic opportunity remains: access to experienced investigators, high-quality sites, and diverse patient populations. The operational requirement, however, is to design submissions, vendor oversight, and essential documentation so you can demonstrate control at any moment—especially as inspection programs mature.

    1) What changed in Brazil’s research governance—and why it matters for sponsors

    Anvisa’s 2025 activity reporting explicitly connects the new ethical law and the updated clinical research regulation to the agency’s current oversight approach (Anvisa). In parallel, Anvisa’s inspection metrics reporting emphasizes inspection readiness against GCP expectations (ICH E6 (R2) or updates) while referencing RDC 945/2024 and Law 14.874/2024 as part of the inspection framework (Anvisa).

    Practical takeaway: even when timelines are competitive, sponsors should assume that documentation quality, vendor governance, and data integrity controls will be evaluated more explicitly. This is good news for well-prepared early-stage teams: strong fundamentals can shorten back-and-forth with sites and reduce downstream remediation.

    2) A sponsor-ready timeline: how to think about “FIH speed” without compliance debt

    Internal execution experience across Latin American programs repeatedly shows that speed usually breaks down in predictable places: incomplete essential documents, misaligned responsibilities between sponsor and CRO, and late-stage changes to protocol and informed consent artifacts. Treat “speed” as a systems outcome rather than a hero effort.

    • Pre-submission (4–8 weeks): lock protocol operational feasibility, confirm investigational product/device logistics, and establish a document control plan.
    • Submission-ready package: create a single source of truth for protocol, IB/IFU (as applicable), safety reporting plan, and data handling plan.
    • Site activation: standardize training, delegation, and vendor onboarding so the first site is not a one-off build.

    Many startups underestimate that “time to first patient” is often constrained by operational readiness, not just authority review. Investing early in a repeatable activation model is one of the highest ROI moves you can make.

    3) Inspection readiness: build once, benefit for years

    Anvisa’s inspection metrics report notes its focus on inspections conducted in 2024 and 2025 and positions inspections as a tool to protect participants and data integrity (Anvisa). For early-stage sponsors, the implication is clear: build inspection readiness into your operating rhythm rather than treating it as a “phase 3 problem.”

    Start with five non-negotiables:

    • Essential document discipline: version control, signatures, and clear ownership.
    • Delegation and training: role-based training mapped to tasks; keep it auditable.
    • Deviation and CAPA workflow: define severity levels and timelines; trend issues.
    • Vendor oversight: documented qualification, KPIs, and periodic review for CROs, labs, and logistics partners.
    • Data integrity: audit trails, access controls, and reconciliation between source, eCRF, and safety database.

    4) How to operationalize this across Latin America (not just Brazil)

    Brazil is rarely the only country in a Latin America strategy. Use Brazil as the quality anchor and replicate the same operating system across additional countries. You can localize what must be localized (ethics committee formats, language, import processes), while keeping your core compliance artifacts stable.

    A useful mental model: create a regional master file (core documents, SOPs, training), plus country modules (local submissions, contracts, import permits), plus site modules (delegation, logs, training, monitoring).

    FAQ

    When did Brazil’s latest clinical research regulations take effect?
    Brazil’s updated framework referenced by Anvisa includes Law 14.874/2024 (in force since 29 Aug 2024) and RDC 945/2024 plus IN 338/2024 (effective 2 Jan 2025).

    Do these changes apply to medical devices too?
    The Anvisa updates cited relate to clinical research for registration of medicines and biologics; device sponsors should still align operational quality systems and inspection readiness to ICH GCP expectations and local ethics requirements.

    How should startups prepare for inspection readiness?
    Build inspection-ready documentation from day one: role-based training, version-controlled essential documents, delegation logs, deviation management, and vendor oversight that can be demonstrated quickly.

    Need help designing a Latin America FIH plan? bioaccess® supports sponsors with regional feasibility, activation, and execution strategies built for speed and inspection readiness.

  • Argentina Just Cut Clinical Trial Import Costs By 50 70%. Here’s What 290 Authorized Trials In 2025 Tell Founders.

    On May 19, 2026, Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) published Disposición 2978/2026, cutting import tariffs on medicines and medical devices by 50 to 70 percent, effective June 1, 2026. The preamble of the instrument states the policy goal explicitly: to attract clinical trial investment to Argentina. The next day, the Argentine government released throughput data that explained why the policy was built: 290 clinical trials authorized in 2025, a 12 percent year-over-year increase, with 114 already authorized in the first quarter of 2026 and 1,188 active studies under ANMAT supervision. Argentina is now formally branding itself an “internationally competitive clinical research hub.”

    For a Latin American clinical research operator who has spent 16 years arguing the speed-and-cost case to MedTech and biopharma founders, the May 19-20 sequence is the most unusual validation event the regulatory landscape has produced this decade. Most LATAM clinical research positioning is CRO marketing. Argentina’s came from the regulator itself, in the preamble of a binding instrument, on government letterhead, with throughput numbers attached. That is not the same kind of evidence as a competitive pitch deck.

    For founders running a 10-patient first-in-human (FIH) device study, the math now stacks in a way that materially changes the country sequencing decision. This post unpacks what changed, what stayed the same, and how founders pursuing a U.S. Early Feasibility Studies (EFS) plus out-of-U.S. (OUS) FIH strategy should think about Argentina in 2026.

    What Changed on May 19, 2026

    Disposición 2978/2026 is the binding instrument. The tariff reduction applies across the import basket relevant to clinical research operations, including investigational drugs, medical devices in trial-supply quantities, reference standards, and disposable consumables tied to study protocols. The pre-existing effective duty rate for imported medical devices in Argentina ranged from 12 to 18 percent before May 19. Under the new schedule, that effective rate compresses to roughly 6 to 12 percent for trial-supply imports, with category-specific reductions ranging from 50 to 70 percent depending on the harmonized system classification.

    On its own, the tariff cut is meaningful. It is more meaningful in combination with the operational baseline Argentina already had in place. Disposición 7516/2025, which came into force in 2025 and is fully aligned with ICH E6(R3), caps clinical trial protocol authorization at 62 calendar days (45 working days maximum). That includes parallel ethics committee review and ANMAT agency review, not sequential review. For comparison, the U.S. EFS pathway typically runs 120 to 180 days from IDE submission to first patient enrolled. Argentina’s ANMAT pathway is 60 to 120 days faster, depending on the comparison case.

    The April 24, 2026 importación simplification further compresses pre-first-patient timelines by removing roughly 14 to 21 days of customs and import-classification delay that previously sat between protocol approval and the actual arrival of study material at site. The June 1, 2026 tariff reduction now removes the cost penalty that previously sat alongside that delay.

    The Throughput Number Most Founders Miss

    The 290-trials-in-2025 figure deserves more attention than it has received. Of those 290 authorizations, the regulator-reported mix is approximately 70 percent biopharma and 30 percent medical device or combination product. The Q1 2026 pace of 114 authorizations annualizes to roughly 456 trials per year, which would represent a 57 percent year-over-year acceleration if sustained. Even if the run rate moderates by half, Argentina’s 2026 throughput will exceed all prior years on record.

    For a founder evaluating site capacity risk, the 1,188 active studies under ANMAT supervision is the more strategic data point. Argentina has the patient-volume depth and the principal-investigator network density to absorb new sponsor demand without the recruitment friction that emerging-market sites with thinner trial histories often impose. A FIH MedTech sponsor running a 10-patient study at two Argentine sites can realistically expect first-patient-in within 90 days of protocol approval, and last-patient-in within 5 to 7 months of contract execution. Those numbers have been stable across the last 36 months of bioaccess® operational experience.

    The Cost Math, Refreshed

    Pre-May 19, 2026, the LATAM per-patient cost range for a FIH MedTech study sat at $15,000 to $35,000, compared to $40,000 to $75,000 in the U.S. and Europe. For a 10-patient FIH device study, that is a $250,000 to $400,000 absolute swing, sufficient on its own to fund roughly four months of clinical operations headcount or a complete adaptive design biostatistics package.

    The June 1 tariff reduction does not move the per-patient labor cost. It moves the device and drug-import cost component, which typically represents 8 to 15 percent of total study cost for a MedTech FIH trial relying on imported investigational devices. A 50 percent reduction on that line item produces a 4 to 8 percent reduction on total study cost, which compounds with the labor cost advantage Argentina already offered. On a $250,000 study, that is an additional $10,000 to $20,000 of effective savings. On a $1 million pivotal-stage Argentine arm of a multi-country trial, the effect grows proportionally.

    The strategic value is not the headline savings number. It is the regulatory clarity that the tariff cut produces. Sponsors evaluating Argentina now know that the regulator has formally committed to clinical research as a strategic policy priority. That changes how a CFO evaluates jurisdiction risk in the IND-enabling phase.

    The Database Anomaly and How to Work Around It

    One operational caveat is worth flagging directly. ANMAT’s public pharmacology database, which historically served as the citable reference for trial throughput and status, remains anchored at a September 30, 2025 data cutoff. As of the publication date of this post, that anomaly has persisted for four consecutive weekly review cycles. The most likely explanation is a backend migration tied to the broader Argentine government’s digital transformation initiative, but the database itself does not yet reflect Q4 2025 or any 2026 data.

    For sponsors building a regulatory dossier or a board pack that requires citable Argentine clinical research throughput data, the May 20, 2026 government statistics package, available through argentina.gob.ar communications channels, is now the more authoritative source than the database. For real-time individual study status, the RENIS (Registro Nacional de Investigaciones en Salud) registry, accessible through the SISA portal, remains operative and current. Disposición 7516/25, the 62-day pathway, the importación simplification, and Disposición 2978/2026 are all fully in force regardless of the database refresh status.

    How to Sequence Argentina in a U.S. EFS Plus OUS FIH Strategy

    The most common 2026 founder question is whether to run U.S. EFS first, OUS FIH first, or both in parallel. The May 19-20 Argentina updates do not change the answer in every case, but they change it in enough cases that the question is worth re-examining.

    For structural heart, neuromodulation, and radiopharmaceutical or theranostic FIH programs, where the U.S. EFS pathway involves an IDE submission with 120 to 180 day review timelines, the parallel Argentina arm is now substantially more attractive. The argument runs as follows: a sponsor who files the IDE with FDA in month one and simultaneously files the ANMAT protocol under Disposición 7516/25 will, in a typical case, have ANMAT approval and first-patient-in achieved before the FDA has finished its initial IDE review. That bridge data, if collected against an FDA-aligned endpoint set, materially strengthens the IDE review and accelerates the post-IDE clinical trial path.

    The bridge data approach assumes the sponsor designs the Argentine arm to match the FDA-expected endpoints from the outset. That is not a regulatory obligation in Argentina, but it is the operational discipline that converts a 62-day pathway into a strategic asset rather than a parallel cost center. ICH M11 CeSHarP, finalized by ICH on May 21, 2026, makes that endpoint-aligned protocol authoring substantially more efficient than it was a year ago.

    For absorbable implants, cardiac ablation, and oncology device FIH programs, the Argentina arm makes sense as the primary FIH site set, with the U.S. EFS following as a confirmatory phase rather than as the primary first-in-human exposure. The 2026 tariff reduction further tips the math in this direction for sponsors with capital constraints between Series A and Series B.

    What This Means for the Latin American Clinical Research Landscape

    Argentina’s May 19-20 sequence is the clearest example to date of a Latin American regulator choosing, in policy, to compete for clinical research investment. Brazil, Mexico, and Colombia have made similar moves in the past 24 months, but none have packaged a binding tariff reduction with a coordinated government statistics release in the same week. The combination is what makes the Argentine moment unusual.

    For Latin American CROs, the strategic implication is that the next 12 to 18 months will likely be a sponsor-favorable market, with multiple jurisdictions actively recruiting trial volume. Sponsors who position now will benefit from regulator attention, expedited review windows, and the willingness of agencies to engage with novel trial designs at the pre-submission stage. Sponsors who delay until the policy environment has fully stabilized will lose the strategic window.

    For bioaccess® and other LATAM operators, the implication is that the value proposition has moved beyond cost and speed into regulatory partnership. The conversation a founder needs to have with their CRO in 2026 is no longer about how fast the trial can run. It is about how the trial design, the country sequence, and the data architecture combine to compress the Innovation Runway, the operational window between a founder’s first FIH decision and the data package their next funding round requires.

    The Bottom Line for Founders

    Argentina has just made the clearest policy statement any Latin American clinical research regulator has produced in 2026. The 62-day pathway under Disposición 7516/25 is operative. The importación simplification is in force. The 50 to 70 percent tariff reduction on imported medicines and medical devices begins June 1. The throughput data confirms that the regulatory environment can absorb new sponsor demand at scale.

    For a MedTech, biotech, or radiopharma founder evaluating a 2026 FIH country sequencing decision, the Argentine arm now warrants serious consideration as the lead site or the parallel site for any program where the U.S. EFS pathway is the comparison baseline. The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong study to run first. Argentina’s May 19-20 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 FIH sequencing decision and want a country-level model that reflects the new Argentina policy environment, the team at bioaccess® can produce a tailored proposal within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • First-In-Human In Brazil In 2026: A Practical Timeline For Sponsors

    First-in-Human in Brazil in 2026: A Practical Timeline for Sponsors

    Primary keyword: first-in-human trial Brazil timeline

    Brazil is increasingly on the shortlist for early-stage clinical development because sponsors can combine a large patient base with growing regulatory clarity. A recent policy analysis argued that Lei 14.874 de 2024 created the basis for a more predictable environment and, for the first time, establishes timelines and greater regulatory clarity for clinical studies.

    This article gives a practical, sponsor-side timeline for launching a first-in-human (FIH) study in Brazil in 2026—what to do first, what typically slows teams down, and how to sequence work so you do not lose weeks to preventable back-and-forth.

    1) Define the “Brazil-ready” FIH package (Weeks 0–2)

    Before any submission, align internal stakeholders on what “Brazil-ready” means. For most MedTech and biopharma sponsors, FIH readiness is not only a protocol question—it is also a documentation and site execution question.

    • Protocol and IB alignment: Ensure endpoints, safety monitoring, and dose-escalation logic are consistent with your global plan.
    • Country adaptations: Identify what must be localized or supplemented (consent language, site materials, labeling, and investigator documentation).
    • Feasibility assumptions: Confirm whether required imaging, lab, or procedural capabilities exist at target sites.

    Internal best practice: Create a single “FIH Brazil master checklist” with owners and due dates. Treat it as a deliverable, not an afterthought.

    2) Select sites for speed, not just prestige (Weeks 1–4)

    In FIH, startup speed is highly correlated with site readiness. Sponsors often choose sites based on reputation, then discover contracting and operational realities late.

    • Prioritize operational maturity: Look for sites with dedicated research staff, established ethics processes, and experience with sponsor audits.
    • Validate recruitment pathways: Treatment-naive populations can be an advantage, but referral networks still matter.
    • Assess import and handling constraints: If your study uses temperature-sensitive materials, confirm storage and chain-of-custody procedures early.

    3) Build a parallel workstream plan (Weeks 2–6)

    The most common timeline mistake is running tasks sequentially that can be executed in parallel. Even when formal review clocks improve, sequential execution can erase the benefit.

    To compress time, run these workstreams at the same time:

    • Regulatory dossier preparation (quality, safety documentation, and trial authorization package)
    • Ethics submission package (site-specific documents and consent)
    • Contracts and budgets (CTA, indemnities, payment schedules, and monitoring model)
    • Supply and logistics readiness (import planning, labeling, storage validation, and back-up scenarios)

    Even when legal reforms aim to improve predictability, sponsors still need coordinated execution across stakeholders to realize those gains.

    4) Anticipate “hidden” startup time: contracts, import, and training (Weeks 4–10)

    Even when review timelines are favorable, sponsors can lose time after approvals due to operational bottlenecks:

    • Contract negotiation cycles: Build buffer time for legal review, redlines, and institutional sign-off.
    • Import and release: If your investigational product or device must be imported, confirm lead times and documentation requirements early.
    • Site initiation and training: FIH trials require strict adherence to safety procedures; schedule training sessions while approvals are in progress.

    Practical tip: Maintain a “go-live readiness dashboard” that tracks contract status, shipment readiness, and training completion. This prevents surprises when the green light arrives.

    5) A sponsor-friendly 2026 FIH timeline (example)

    Every program is different, but a realistic planning template looks like this:

    • Weeks 0–2: Brazil-ready protocol package, checklist, and internal alignment
    • Weeks 1–4: Site selection, feasibility, and early budget/CTA drafts
    • Weeks 2–6: Parallel dossier + ethics package finalization
    • Weeks 4–10: Contracts, import planning, training, and vendor setup
    • Weeks 10–14: Final site activation steps and first-patient readiness

    If you are aiming for speed, measure time-to-ready as rigorously as you measure time-to-approval. In many FIH programs, the fastest sponsors are simply the ones that avoid rework.

    FAQ: First-in-human trial Brazil timeline

    • How long does it take to start a first-in-human trial in Brazil?
      Timelines vary by protocol complexity and site readiness, but sponsors should plan for parallel regulatory and ethics pathways, early document localization, and realistic contracting and import lead times.
    • What is the biggest cause of FIH delays in Brazil?
      In practice, delays often come from incomplete documentation, late site selection, and underestimated startup logistics (contracts, import permits, and investigational product readiness), not just the formal review clock.
    • Can Brazil FIH data support US or EU submissions?
      Yes, when the trial is designed to international GCP standards and endpoints align with your global regulatory strategy, Brazilian data can be part of a broader evidence package.

    Need help planning an FIH startup in Brazil or across Latin America? bioaccess® supports sponsors with country startup planning, site activation, and operational execution—without exposing confidential details publicly.

  • Brazil’s 90‑Business‑Day ANVISA Clock: How to Plan First‑in‑Human Activation Without Bottlenecks

    Brazil’s 90‑Business‑Day ANVISA Clock: How to Plan First‑in‑Human Activation Without Bottlenecks

    Brazil has moved from “unpredictable timelines” to a more clock-driven model for key clinical trial petitions. According to the U.S. NIH ClinRegs Brazil overview, Law No. 14.874 requires ANVISA’s analysis of primary petitions for clinical trials (including Clinical Drug Development Dossiers, DDCMs) to be completed within 90 business days. This is a meaningful planning advantage for MedTech and Biopharma teams designing first‑in‑human (FIH) or other early-stage studies in Latin America.

    But a defined regulator timeline does not automatically translate into a fast first-patient-in. Activation can still stall due to ethics sequencing, site contracts, import permits, labeling, budgeting, and operational readiness. The sponsors who benefit most are the ones who orchestrate the entire activation system around the review clock—not just the regulatory submission.

    This article provides a practical playbook for using Brazil’s defined review window to reduce uncertainty without compromising compliance. It is written for MedTech founders, clinical operations leaders, and regulatory directors planning early clinical evidence generation in Latin America.

    1) What the “90‑business‑day clock” means (and what it doesn’t)

    In many countries, the biggest activation challenge is not the technical content of the dossier—it is uncertainty. When timelines drift, every downstream dependency becomes harder: site selection, device logistics, vendor contracting, and financing.

    Brazil’s framework has introduced a clearer expectation. ClinRegs summarizes that ANVISA’s analysis of primary petitions for clinical trials with human beings “must be completed within 90 business days” under Law No. 14.874, with related implementing details in Resolução RDC No. 945 (including how the 90 business days are counted for DDCM/DEEC petitions).

    Important nuance: a regulator timeline is one piece of a multi-track activation pathway. If the sponsor treats the ANVISA clock as the entire schedule, they can still lose weeks or months elsewhere.

    2) Build an activation timeline like a network, not a checklist

    Fast activation is usually the result of parallelization, not heroics. A useful way to plan is to treat each workstream as a node in a network:

    • Regulatory dossier readiness (DDCM/DEEC content, translations, country-specific annexes)
    • Ethics committee readiness (Brazil CEP/CONEP strategy, submissions, anticipated questions)
    • Site readiness (feasibility, equipment, training, contracts, budgets)
    • Import and logistics readiness (customs broker, labeling, packaging, temperature control, returns)
    • Data and safety operations (eCRF build, SAE workflows, vendor setup, monitoring plan)

    In early-stage MedTech programs, the “critical path” often shifts midstream. For example, the device may be available, but site contract negotiation drags. Or the site is ready, but import documentation is incomplete. A network view helps you see what must be done in parallel so that the 90-day review window is not wasted.

    3) A practical pre-submission readiness package (what to have done before day 0)

    To benefit from predictable review windows, sponsors should aim to begin ANVISA review with minimal “churn” during the clock. In practice, this means building a readiness package before the submission date. Common elements include:

    • Protocol that is operationally executable: endpoints, visit schedule, and device handling that local sites can implement.
    • Risk-driven monitoring and safety plan: proportional to first-in-human risk, with clearly defined escalation pathways.
    • Brazil-ready informed consent: culturally appropriate language; processes for re-consent if amendments occur.
    • Import map: who will act as importer-of-record, how devices will be labeled, and the evidence trail for traceability.
    • Site contracts and budgets in draft form: so legal review does not become the gating item after regulatory clearance.

    Internal experience across Latin America shows that when sponsors plan only the submission, they often discover the “real bottleneck” later. Conversely, when they package readiness early, they can compress time-to-site-initiation after regulatory clearance.

    4) Common activation bottlenecks in Brazil (and how to design around them)

    Even with a defined regulator timeline, teams can lose time in avoidable areas. Here are recurring bottlenecks and practical ways to design around them:

    • Ethics sequencing misunderstandings: plan early for CEP/CONEP pathways and expected document sets; align translations and investigator documents up front.
    • Device logistics not protocolized: define receipt, storage, accountability, and disposal processes inside the protocol and site manuals.
    • Training delays: schedule investigator meetings and device training as soon as sites are selected; do not wait for final approvals to build training assets.
    • Budget misalignment: ensure site budgets reflect local realities (procedures, imaging, follow-up) to reduce renegotiation cycles.

    Operationally, the fastest programs are those where regulatory and operations leaders co-own the activation timeline, instead of treating it as a handoff from “regulatory” to “clinops.”

    5) How to use Brazil’s timeline advantage in a multi-country Latin America strategy

    Brazil’s defined review window can be especially valuable when used as one “anchor country” in a broader Latin America evidence strategy. Sponsors often seek to generate credible early data quickly, then expand into additional markets.

    To do this effectively:

    1. Design the protocol for exportability: align endpoints and data standards with future regulatory and reimbursement conversations.
    2. Standardize your core dossier: build a master package that can be adapted for different authorities without reinventing content.
    3. Plan the expansion pathway early: identify which countries can open in parallel (based on timelines, import complexity, and site readiness).

    For example, NIH ClinRegs indicates Peru’s INS must complete review and approval of a clinical trial application within a maximum of 30 working days, which may influence sequencing decisions depending on site availability and import readiness. The right path depends on the sponsor’s risk tolerance, funding timeline, and clinical endpoints.

    FAQ: Brazil’s ANVISA clock and first‑in‑human planning

    How long does ANVISA have to review key clinical trial petitions in Brazil?

    NIH ClinRegs summarizes that, under Law No. 14.874, ANVISA’s analysis of primary petitions for clinical trials (including DDCMs) must be completed within 90 business days.

    Does a 90-business-day regulator timeline guarantee fast first-patient-in?

    No. Activation speed depends on the entire system: ethics reviews, site contracts, import logistics, training, and operational readiness. A defined review window reduces uncertainty, but sponsors still need parallel planning.

    What is the biggest mistake sponsors make when planning first‑in‑human studies in Brazil?

    Treating regulatory submission as the whole project. The most common failure mode is not “regulatory delay”—it is downstream operational bottlenecks that were not designed into the timeline.

    Bottom line: Brazil’s defined review timeline can be a real advantage for early-stage programs, but only if sponsors plan activation as a coordinated set of parallel workstreams. If you treat the 90-day clock as a project management tool—not just a legal detail—you can reduce uncertainty and protect your first-patient-in date.

  • Ophthalmic First-In-Human Studies In Latin America: Why Smaller Markets Often Move Fastest

    Ophthalmic First-in-Human Studies in Latin America: Why Smaller Markets Often Move Fastest

    For ophthalmic medical device founders running their first-in-human (FIH) program — intravitreal injectors, glaucoma microshunts, retinal delivery platforms, intraocular lens innovations — the conventional wisdom says you go to a country with the largest patient pool and the most prestigious eye institutes. In Latin America, that usually points sponsors toward Mexico or Brazil first.

    That instinct is right for pivotal studies. For an FIH or early-feasibility study with 5 to 15 patients, however, our operational experience consistently shows a different pattern: smaller markets like El Salvador, Panama, and the Dominican Republic often deliver a faster path to first patient in. Here is why, and how to think about country selection for an ophthalmic FIH program.

    The FIH Math Is Different from the Pivotal Math

    Pivotal studies select for patient pool depth, statistical power, and reimbursement signal. FIH studies select for something else entirely: speed to first dose, regulatory predictability, and quality of investigator engagement on a small handful of patients.

    For a 10-patient ophthalmic FIH study, the binding constraint is rarely “are there enough eligible patients in the country” — almost any LATAM country has thousands of glaucoma, AMD, or refractive candidates. The binding constraints are:

    • Time from sponsor decision to first ethics committee submission
    • Time from EC approval to first patient screened
    • Investigator focus and availability across the dosing window
    • Regulatory predictability for a novel device class

    On all four, smaller markets often outperform the regional giants for FIH-stage work.

    Why Smaller Markets Move Faster on Ophthalmic FIH

    Three structural factors explain it.

    1. Lighter EC and regulatory queues. An ethics committee at a leading eye hospital in El Salvador or Panama might review three to six device protocols per quarter. The equivalent committee at a top São Paulo or Mexico City institute might be working through 30 to 60. Both are competent and rigorous; one simply has more capacity for a fast-track FIH protocol.

    2. Concentrated investigator attention. In smaller markets, a leading ophthalmologist running an FIH study is not splitting attention across 12 simultaneous trials. The principal investigator has direct line of sight on every screening visit, every dosing event, every follow-up — the kind of operational intimacy that materially reduces protocol deviations and data queries on a small-N study.

    3. Tighter sponsor-to-site communication. Smaller hospital systems mean fewer layers between sponsor, CRO, principal investigator, and ethics coordinator. A protocol clarification that takes a week to circulate at a large academic center can be resolved in a 30-minute call in a smaller setting.

    What This Looks Like in Practice for an Ophthalmic FIH

    For an intravitreal device, glaucoma microshunt, or refractive implant FIH program, a well-structured small-market approach typically looks like this:

    • Single-country FIH (5–10 patients). Concentrate enrollment at one or two specialized eye centers in a smaller market. Optimize for speed and data quality, not geographic diversity.
    • Validated translation and regulatory packets ready before EC submission. Smaller markets are fast on substance but unforgiving on document inconsistency.
    • Compressed feasibility-to-FPI window. A 6 to 8 week target from sponsor go-decision to first patient enrolled is achievable when site, EC, and country regulator are aligned from day one.
    • Clean handoff to a multi-country pivotal. Once FIH safety data is in hand, the pivotal can move to Mexico, Brazil, Argentina, or a multi-country footprint with the FIH evidence already supporting site selection conversations.

    When the Conventional Path Still Wins

    Smaller markets are not the right choice for every ophthalmic FIH. Three situations argue for going to Mexico or Brazil first:

    • Genetic ophthalmic indications where a specific sub-population is concentrated in one large country.
    • Complex imaging endpoints requiring a specific OCT, ultra-widefield imaging, or AI-assisted analysis platform that is only operational at a handful of large academic centers in the region.
    • Founder-led key opinion leader strategy where the FIH publication-to-investor narrative depends on a specific principal investigator’s involvement.

    For most early-stage ophthalmic device sponsors, however, the speed advantage of smaller markets at the FIH stage translates directly into reduced cash burn during the most capital-fragile window of the company’s life. In an industry where 90% of MedTech startups fail because they run out of capital before generating clinical evidence, that compression matters.

    Frequently Asked Questions

    How quickly can a well-designed ophthalmic FIH actually start in a smaller LATAM market?
    With prepared documents, an experienced site, and a clear regulatory pathway, 6 to 10 weeks from contract signature to first patient screened is realistic. The variability comes from how prepared the sponsor’s regulatory packet is, not from the country’s regulatory speed.

    Will FDA accept FIH data from El Salvador, Panama, or the Dominican Republic?
    Yes, under 21 CFR 812.28, provided the study is conducted in compliance with ICH-GCP. The FDA does not maintain a country whitelist; it evaluates each study on the quality of its execution, documentation, and ethics oversight.

    Should we run the FIH in a smaller market and then move the pivotal to Brazil or Mexico?
    This is a common and effective sequencing strategy for ophthalmic device programs. Smaller markets optimize for speed at the FIH stage. Larger markets optimize for enrollment depth, infrastructure, and regulatory signal at the pivotal stage. Designing the FIH protocol with the eventual pivotal in mind — same imaging modalities, same primary endpoint definitions, same data capture standards — makes the transition seamless.

    bioaccess® is the world’s only contract research organization built exclusively for first-in-human medical device trials, operating across 10 Latin American countries. Explore the FIH playbook at bioaccessla.com or estimate a study at bioaccessla.com/clinical-trial-calculator.

  • Brazil’s 90‑Business‑Day ANVISA Clock: A First‑in‑Human Activation Timeline for MedTech

    Brazil’s 90‑Business‑Day ANVISA Clock: A First‑in‑Human Activation Timeline for MedTech

    For MedTech founders and regulatory directors, “first patient in” is not a single milestone—it is the outcome of dozens of parallel workstreams that must converge at the right time. Brazil has become an increasingly attractive environment for early-stage studies because the country’s regulatory pathway has defined review timelines for parts of the process, including a 90-business-day window for ANVISA’s analysis of key clinical trial petitions as described by the U.S. NIH’s ClinRegs Brazil overview.

    But a fast clock on paper does not automatically translate into a fast activation in practice. Sponsors still lose weeks when ethics submissions, ANVISA dossiers, import readiness, and site enablement are treated as sequential tasks rather than an integrated program. This article provides a practical first-in-human (FIH) activation timeline for Brazil—designed for medical devices and combination products—so teams can predict the critical path, reduce avoidable rework, and protect study quality.

    Why Brazil is different for early-stage activation

    Brazil’s clinical research oversight operates as a dual system. On the regulatory side, ANVISA is responsible for clinical trial oversight, approvals, and inspections. On the ethics side, institutional Research Ethics Committees (CEPs) and the National Research Ethics Commission (CONEP) safeguard participant rights and may be required for certain studies, including some with foreign sponsorship. ClinRegs notes that clinical trials may only begin after both ethics and ANVISA approvals are in place, and that sponsors can submit in parallel rather than waiting for one decision before starting the other.

    For FIH programs, the key operational insight is that “parallel” only works if your team pre-builds the dossier and operational backbone in a way that prevents late-stage gaps. That means aligning protocol, investigator’s brochure (or device equivalent), risk management, investigational product logistics, and site readiness into one activation plan.

    A practical FIH activation timeline (week-by-week)

    The timeline below is a planning template. Your specific path will vary based on device risk class, whether the product is a device-only investigation or a drug-device combination, whether import is required, and whether CONEP review applies. Still, most FIH teams benefit from managing the activation plan as six overlapping phases.

    Phase 1 (Weeks 0–2): Activation blueprint and dossier alignment

    • Define the activation goal: first patient in, first-in-country, or first site activated—then translate it into a dated plan with owners.
    • Freeze core scientific documents: protocol, statistical approach (if applicable), investigator brochure/device technical file summary, informed consent draft, and safety monitoring plan.
    • Pre-brief sites: confirm investigator interest, feasibility, patient pool, and required imaging/lab capabilities.
    • Map the import path: determine whether investigational product import will be needed, what documents are required, and when to initiate customs planning.

    Common pitfall: teams treat feasibility as “business development,” then discover late that the site cannot execute key assessments. For FIH studies, feasibility should be treated as a protocol risk-control activity.

    Phase 2 (Weeks 2–4): Parallel submission readiness (ethics + ANVISA)

    ClinRegs indicates that clinical trial applications can be submitted in parallel in Brazil. Use that advantage. Your objective in this phase is not merely to “submit,” but to submit dossiers that survive the first pass without avoidable queries.

    • Ethics package readiness: ensure Portuguese-language materials, recruitment approach, participant protections, investigator CVs, and site documentation are complete.
    • Regulatory package readiness: align device description, risk analysis, prior testing, clinical rationale, and monitoring approach into an internally consistent narrative.
    • Operational readiness: contract templates, budget assumptions, data capture approach, and vendor onboarding plan.

    Tip: run an internal “approval simulation” meeting before submission. Ask: if the reviewer questions the risk–benefit logic, do we have a clear answer embedded in the dossier?

    Phase 3 (Weeks 4–10): Review window management and rapid-response loop

    ClinRegs describes a 90-business-day timeframe for ANVISA’s analysis of key clinical trial dossiers, with defined sponsor response windows when additional information is requested. Even with set timelines, the sponsor’s responsiveness and document discipline often determine whether the review stays on track.

    • Stand up a “question-response” war room: pre-assign technical owners (clinical, quality, regulatory, biostatistics, logistics) so questions can be addressed within days, not weeks.
    • Maintain a single source of truth: track every submitted document version and every response in a controlled repository.
    • Keep sites warm: train coordinators, initiate essential vendor qualification, and prepare for SIV scheduling so you can start immediately after approvals.

    Common pitfall: teams wait for approval before planning site initiation, then lose 2–4 weeks to avoidable scheduling and vendor delays.

    Phase 4 (Weeks 8–12): Import and investigational product readiness

    FIH programs fail more often from logistics than from science. If you need to import devices, kits, or ancillary supplies, design the import process as a parallel track, not an afterthought.

    • Confirm labeling and packaging requirements: ensure your investigational labeling supports clinical-use workflows and aligns with the protocol.
    • Build a customs-ready document pack: commercial invoice equivalents, certificates, and product descriptions that minimize ambiguity.
    • Create a buffer strategy: hold contingency inventory or stage supplies locally when feasible.

    Tip: for FIH devices, plan at least one “mock shipment” exercise or logistics rehearsal, even if it’s document-only. The point is to find gaps while time remains.

    Phase 5 (Weeks 10–14): Site initiation and first patient in

    • Run targeted SIVs: prioritize protocol-critical procedures, safety reporting, and data integrity steps.
    • Operationalize screening: define screening triggers, referral pathways, and investigator decision trees.
    • Monitor early execution: the first 1–3 patients usually reveal whether your trial design is workable in the real world.

    Common pitfall: launching without clear screening criteria and without real-time visibility into early deviations. For FIH, early deviations often signal that the trial design needs operational adjustments.

    Phase 6 (Weeks 14+): Stabilize, scale sites, and protect data quality

    • Scale site network deliberately: expand only after the first site demonstrates protocol adherence and predictable enrollment.
    • Harden the safety loop: ensure rapid reporting, investigator training, and sponsor review cadence.
    • Maintain audit readiness: document control and deviation management are not optional; they are how you preserve the value of your data for future submissions.

    Checklist: What to pre-build before you submit

    • Protocol + operational workflow map (how each visit is executed at the site)
    • Device/technology summary that is consistent across regulatory, ethics, and site materials
    • Risk management narrative that ties hazards to mitigations and monitoring
    • Import-readiness pack with clear product descriptors and shipping plan
    • Vendor onboarding plan (labs, imaging, data capture, logistics) aligned to activation dates
    • Response war room with named owners and draft response templates

    FAQ

    1) Can we submit to ethics and ANVISA at the same time in Brazil?

    Yes. ClinRegs indicates that clinical trial applications can be submitted in parallel, but trials should not start until both approvals are in place. The operational value is in reducing idle time by building parallel readiness workstreams.

    2) What typically delays first-in-human activation the most?

    In many FIH programs, delays come from late dossier inconsistencies, slow responses to reviewer questions, and underestimated import and site-startup tasks. Treat activation as a program with a critical path rather than a compliance checklist.

    3) How do we protect data quality while moving fast?

    Move fast by reducing rework—not by cutting corners. Standardize document control, train sites on protocol-critical steps, and implement real-time deviation monitoring so you can correct execution issues early.

    Educational content only. Sponsors should consult qualified regulatory and clinical research professionals for study-specific planning.

  • Brazil’s 90‑Day ANVISA Clock for First‑in‑Human MedTech Studies: A Sponsor-Ready Timeline

    Brazil’s 90‑Day ANVISA Clock for First‑in‑Human MedTech Studies: A Sponsor-Ready Timeline

    For MedTech founders and regulatory leaders, the difference between a credible first‑in‑human (FIH) plan and an expensive science project often comes down to one question: when will we be cleared to start? In Latin America, Brazil is increasingly attractive because the regulatory environment is becoming more predictable for sponsors who prepare correctly. The biggest practical shift is that Brazil’s current framework is designed around a defined review window for ANVISA’s assessment of primary clinical‑trial petitions.

    This article translates that “clock” into a sponsor-ready activation timeline—what to do first, what can run in parallel, and where teams still lose weeks. It is written for early-stage device companies planning a first-in-human or very early feasibility study and aiming to use Brazil’s speed without compromising compliance.

    1) What the “ANVISA clock” changes (and what it does not)

    A defined review window is only valuable if your submission is complete and internally consistent. In practice, teams still face delays from avoidable dossier defects, mismatched translations, missing proof of manufacturer authorization, or unclear risk management documentation.

    • What changes: Sponsors can build a tighter critical path because the regulatory review is no longer an open-ended variable.
    • What does not change: Poor dossier quality, unclear clinical rationale, and weak local operational readiness can still extend the activation timeline.

    Think of the “90-day clock” as a predictability multiplier. It rewards teams that treat activation as a program, not a document handoff.

    2) A sponsor-ready activation timeline for FIH MedTech studies in Brazil

    Below is a practical timeline for a single-country Brazil activation that is common for early-stage MedTech programs. Actual sequencing depends on device risk classification, study design, and whether you already have an audited quality system and finalized manufacturing documentation.

    Phase A (Weeks 0–2): Define your regulatory “story” and activation plan

    Before drafting anything, align internal stakeholders on four elements:

    • Clinical intent: What data must your FIH generate (safety, usability, performance, feasibility) to unlock your next milestone?
    • Risk position: A simple, defensible summary of hazards, mitigations, and residual risk.
    • Operational model: Which hospitals, investigators, and vendor partners can execute within your required timeline?
    • Regulatory endpoints: Which approvals are required (ethics, ANVISA, contracts, importation readiness) and what is the critical path?

    Common failure mode: Teams finalize the protocol without deciding how the device will be imported, stored, serviced, and returned—creating late-stage amendments and logistics rework.

    Phase B (Weeks 2–6): Build the dossier as an integrated package

    FIH dossiers fail not because the science is wrong, but because the package is incoherent. Aim to produce a “single narrative” across these documents:

    • Protocol + investigator materials: Clear objectives, endpoints, and monitoring plan.
    • Device technical file excerpts: What the device is, how it works, and how it is controlled.
    • Risk management + usability: Evidence that use-related risks are addressed in training, labeling, and design controls.
    • Manufacturing and quality evidence: Enough to support safety and traceability expectations.
    • Clinical rationale: Why FIH is appropriate now and why Brazil’s sites can execute safely.

    Best practice: Maintain a “regulatory crosswalk” table mapping each claim in the protocol (device description, intended use, risk controls) to supporting evidence in the technical file. This prevents contradictions that trigger regulator questions.

    Phase C (Weeks 4–8): Ethics readiness and site operational lock

    While the dossier is being finalized, lock down the operational prerequisites that routinely delay activation:

    • Site feasibility confirmation: Not generic interest—confirmed equipment compatibility, OR slots, and patient flow.
    • Contracts and budget: Early alignment with hospital administration avoids last-minute legal stalls.
    • Training plan: How will you prove investigator training and competency for first uses?
    • Device logistics: Importation responsibilities, packaging validation, and field support processes.

    FIH timelines improve when ethics, contracts, and logistics are treated as first-class workstreams—not “post-approval tasks.”

    Phase D (Weeks 8–20): Regulatory review window and question management

    Once submitted, your main objective is to minimize cycles. Even with a defined review window, questions can reset practical timelines. Sponsors can reduce rework by planning for:

    • Rapid response capability: A named owner who can coordinate answers across engineering, QA/RA, and clinical.
    • Document control discipline: Consistent versioning, translation control, and traceability of edits.
    • Pre-drafted evidence packets: Sterilization summary, labeling package, risk management summary, device master record excerpts.

    Tip: When responding to questions, avoid “new storylines.” Keep answers anchored to the original intended use and risk position unless a formal amendment is required.

    3) Where FIH teams still lose time in Brazil

    Even with improved predictability, sponsors still lose weeks in three recurring areas:

    • Under-scoped translations: Technical and clinical translations require domain expertise, not generic language services.
    • Unclear importer/registration model: If responsibilities for importation and regulatory representation are not defined, device availability becomes the bottleneck.
    • Late site readiness: Contracts, budgets, and first-case scheduling often lag behind the regulatory path.

    The fix is not “work faster.” The fix is to design an activation system where regulatory, quality, and operations are integrated from day one.

    4) A practical checklist before you start your FIH activation

    • Have we defined the minimum FIH dataset required for our next financing or partnership step?
    • Is our intended use and risk position consistent across protocol, device description, and labeling?
    • Do we have a locked plan for importation, storage, servicing, and returns?
    • Are our sites contract-ready with budgets aligned and first-case logistics mapped?
    • Do we have a “rapid response” team prepared for regulator questions?

    FAQ: Brazil first‑in‑human MedTech study activation

    1) Can a defined review window guarantee my exact start date?

    No. It improves predictability, but start dates still depend on dossier quality, question cycles, ethics timing, contracts, and logistics.

    2) What is the most common avoidable delay for early-stage sponsors?

    Incoherent documentation—contradictions between protocol claims and device evidence, plus weak translation and version control.

    3) Should we activate Brazil as a stand-alone FIH or part of a multi-country plan?

    Many MedTech startups start with a focused single-country activation to generate clean early human data quickly, then expand once operational learning is captured.

    Conclusion: Brazil’s evolving framework can give FIH sponsors a more predictable regulatory path—but only if you build a dossier and activation plan that is operationally executable. Treat the “ANVISA clock” as a program milestone, not a date, and you can turn regulatory predictability into faster, safer first-in-human learning.

  • How to Conduct First-in-Human Trials in Bolivia: 4 Essential Steps

    How to Conduct First-in-Human Trials in Bolivia: 4 Essential Steps

    Introduction

    Conducting first-in-human trials in Bolivia is not just an opportunity; it’s a complex challenge that can redefine MedTech and Biopharma innovations. By understanding the essential steps and regulatory landscape, researchers can streamline their clinical trial processes, enhancing compliance and efficiency.

    Navigating AGEMED and INVIMA regulations can be daunting, often leading to delays and complications. What strategies can ensure timely approvals while effectively recruiting participants in a diverse environment? Mastering these regulations not only accelerates approvals but also enhances participant recruitment.

    Understanding these components is essential for executing trials successfully, offering insights that could shape the future of medical advancements in Latin America.

    Understand Regulatory Requirements for First-in-Human Trials in Bolivia

    Navigating the regulatory landscape on how to conduct first-in-human trial Bolivia can be daunting, but understanding the framework set by AGEMED and INVIMA is essential for success. Here are the essential steps to ensure compliance:

    1. Familiarize Yourself with AGEMED Regulations: Review AGEMED’s guidelines, which govern clinical study approvals in Bolivia. This includes understanding the necessary documentation and ethical considerations required for submission.
    2. Prepare Required Documentation: Compile essential documents such as the clinical study protocol, informed consent forms, and investigator brochures. Ensure these documents align with ICH-GCP standards to facilitate a smoother approval process.
    3. Submit for Ethical Review: Submit your trial protocol to an ethics committee for review. This process typically takes 30-60 days. Address all ethical considerations, including patient safety and informed consent, to avoid delays. Have you considered how these factors might impact your timeline?
    4. Obtain Regulatory Approval: After receiving ethical approval, submit your application to AGEMED. The approval process can take approximately 60-90 days. Be prepared to respond promptly to any queries or requests for additional information from AGEMED.
    5. Maintain Adherence Throughout the Study: Once approved, ensure adherence to all compliance requirements, including regular reporting and monitoring of study progress. This diligence helps mitigate risks and ensures the integrity of your study.

    By leveraging bioaccess’s resources and following these steps, you can learn how to conduct first-in-human trial Bolivia, streamlining your path to successful clinical trials while ensuring compliance and efficiency.

    Each box represents a crucial step in the process of conducting clinical trials. Follow the arrows to see how each step leads to the next, ensuring you understand the entire pathway to compliance and success.

    Select an Appropriate CRO for Your First-in-Human Trial

    Choosing the right CRO is critical for your research’s success when considering how to conduct first-in-human trial Bolivia. Here are essential steps to guide your decision:

    1. Evaluate Experience with FIH Studies: Select a CRO with a strong history in conducting FIH studies pertinent to your therapeutic area. Look for documented case studies or testimonials that highlight their expertise and success in similar studies, such as those from bioaccess®, which has successfully guided over 60 companies through the clinical development pathway.
    2. Evaluate Regulatory Knowledge: The CRO must have comprehensive knowledge of Bolivian regulations, particularly those set by AGEMED (Agencia Nacional de Regulación y Control Sanitario) and INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos). Understanding these requirements can greatly accelerate the approval process, which generally lasts 4 to 8 weeks for FIH studies. Understanding ANVISA regulations is also crucial for ensuring compliance and efficiency.
    3. Consider Local Presence: A CRO with a local footprint can effectively navigate the compliance landscape and enhance recruitment efforts. Established connections with local ethics committees and regulatory bodies are essential for seamless operations, ensuring that the study can advance without unnecessary delays.
    4. Review Operational Capabilities: Assess the CRO’s operational strengths, including site management, patient recruitment strategies, and data management systems. Ensure they can offer extensive support throughout the study lifecycle, from initiation to completion. bioaccess®’s Innovation Runway is designed to accelerate clinical milestones, helping startups reach their goals faster.
    5. Discuss Cost and Timeline Efficiency: Engage in discussions regarding cost structures and timelines. A CRO that demonstrates cost efficiency-potentially reducing costs by 30% compared to traditional US/EU approaches-while maintaining high-quality standards is essential for startups operating under tight budgets. Understanding how to conduct first-in-human trial Bolivia can help in utilizing the strategic benefits of conducting studies in Latin America, resulting in substantial savings and quicker timelines.
    6. Conduct Interviews and Site Visits: Before making a final decision, conduct interviews with key personnel and, if feasible, visit their facilities. This will provide insights into their operational processes and team dynamics, ensuring alignment with your project goals. Consider how bioaccess® has successfully supported numerous MedTech and Biopharma startups in navigating these critical steps.

    The right CRO can be the difference between a successful study and a costly setback, so choose wisely.

    This flowchart guides you through the essential steps for choosing the right CRO. Each box represents a step in the process, and the arrows show the order in which you should tackle them. Following these steps can help ensure a successful trial.

    Design a Comprehensive Trial Protocol

    Understanding how to conduct first-in-human trial Bolivia involves navigating the complexities that require a meticulously crafted protocol to ensure compliance and optimize outcomes. Here are the critical steps to consider:

    1. Define Study Objectives: Clearly articulate the primary and secondary objectives of the research. This foundational step guides the overall study design and helps in determining specific endpoints that align with regulatory expectations.
    2. Select Study Design: Choose an appropriate study design, such as a randomized controlled study or cohort study, that aligns with your objectives. Consider essential factors like sample size, control groups, and blinding methods to enhance the validity of your findings.
    3. Develop Inclusion and Exclusion Criteria: Specify the eligibility criteria for participants to ensure that the study population is suitable for the research questions being addressed. This step is crucial for maintaining the integrity of the trial and ensuring compliance with local regulations set by authorities like INVIMA.
    4. Outline Methodology: Detail the methods for data collection, including procedures for administering the investigational product, monitoring patient safety, and collecting outcome measures. Ensure that these methods adhere to ICH-GCP guidelines, which are crucial for ethical approval and compliance. Understanding how to conduct first-in-human trial Bolivia enables ethics approvals in just 4-8 weeks, which is significantly faster than in the US/EU, thus facilitating quicker access to clinical data.
    5. Plan for Data Management and Analysis: Describe how data will be managed, including collection methods, storage, and analysis plans. This should include statistical methods for analyzing both primary and secondary endpoints, ensuring that the analysis aligns with compliance expectations.
    6. Include Ethical Considerations: Address ethical considerations, including informed consent processes and how participant confidentiality will be maintained. This is essential for obtaining ethical approval from local oversight bodies and ensuring participant trust.
    7. Review and Revise: Conduct a thorough review of the protocol with your team and stakeholders before finalization. Revise as needed to ensure clarity, adherence to standards, and alignment with best practices in clinical research.

    Neglecting these critical steps could delay your research and hinder market access, making a robust protocol not just beneficial, but essential.

    Each box represents a step in the protocol design process. Follow the arrows to see how each step leads to the next, ensuring a thorough and compliant trial setup.

    Implement Effective Patient Recruitment Strategies

    To successfully recruit patients for how to conduct first-in-human trial Bolivia, you must navigate unique challenges and leverage local resources effectively. Consider the following strategies:

    1. Collaborate with Local Physicians: Work with local healthcare providers to raise awareness about the study. Their established credibility can help identify potential participants and foster trust within the community. Involving local healthcare providers is essential, as they can connect the trial with the population, addressing concerns and misconceptions directly.
    2. Engage Advocacy Groups: Partner with organizations focused on the condition being studied. These groups can aid in outreach initiatives and provide valuable insights into the needs and concerns of individuals, enhancing the relevance of your recruitment strategies.
    3. Leverage Digital Platforms: Utilize social media and online patient communities to reach a broader audience. Digital platforms enhance engagement and offer crucial information regarding the study, simplifying the process for potential participants to discover opportunities and advantages.
    4. Conduct Community Outreach: Organize informational sessions in local communities to educate potential participants about the study. Address common misconceptions and emphasize the benefits of participation, such as access to cutting-edge treatments and the opportunity to contribute to medical advancements.
    5. Implement Flexible Enrollment Processes: Offer adaptable enrollment options, such as telehealth consultations, to accommodate individuals’ needs and increase participation rates. This approach can greatly diminish logistical obstacles, facilitating easier engagement for patients with the study.
    6. Monitor Recruitment Progress: Regularly assess recruitment metrics to identify challenges and adjust strategies as needed. This proactive strategy assists in maintaining momentum and ensures prompt enrollment, which is essential in understanding how to conduct first-in-human trial Bolivia in a fast-paced environment.
    7. Provide Clear Communication: Make sure your communication with potential participants is straightforward and open. Provide detailed information about the study, including risks, benefits, and the informed consent process. Clear communication fosters trust and encourages participation, as individuals feel more informed and valued.

    Addressing these challenges head-on will not only enhance recruitment but also accelerate the pace of medical innovation in the region.

    The central node represents the main goal of effective patient recruitment. Each branch shows a different strategy to achieve this goal, with sub-branches providing additional details. This layout helps you see how each strategy connects to the overall objective.

    Conclusion

    Successfully navigating first-in-human trials in Bolivia hinges on a deep understanding of regulatory frameworks and strategic operational choices. This includes selecting the right contract research organization (CRO), designing meticulous protocols, and implementing effective patient recruitment strategies. Each of these elements plays a pivotal role in ensuring the success of clinical trials. Without a clear understanding of these elements, the success of clinical trials may be jeopardized, delaying access to innovative therapies for patients in need.

    Key steps outlined include:

    1. Familiarizing oneself with AGEMED regulations
    2. Preparing essential documentation
    3. Securing ethical approval

    These are crucial for compliance and efficiency. Selecting a CRO with relevant experience and local knowledge can significantly expedite the approval process while ensuring that the study adheres to local regulations. It’s essential to craft a robust trial protocol that clearly defines your study objectives and methodologies to achieve reliable outcomes. Lastly, implementing tailored patient recruitment strategies can enhance participation rates, facilitating smoother trial execution.

    The potential of conducting first-in-human trials in Bolivia extends beyond regulatory compliance and operational efficiency. This potential opens doors to accelerated medical innovation that can significantly impact patient care. By embracing these strategic insights, researchers not only enhance trial success but also play a crucial role in shaping the future of healthcare.

    Frequently Asked Questions

    What are the key regulatory authorities for conducting first-in-human trials in Bolivia?

    The key regulatory authorities for first-in-human trials in Bolivia are AGEMED (Agencia Estatal de Medicamentos y Tecnología en Salud) and INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos).

    What initial steps should be taken to comply with AGEMED regulations?

    To comply with AGEMED regulations, familiarize yourself with their guidelines, prepare the necessary documentation, and understand the ethical considerations required for submission.

    What documentation is required for submitting a clinical study in Bolivia?

    Required documentation includes the clinical study protocol, informed consent forms, and investigator brochures, all of which must align with ICH-GCP standards.

    How long does the ethical review process take for a clinical trial protocol?

    The ethical review process typically takes 30-60 days.

    What should be included in the ethical review submission?

    The trial protocol submitted for ethical review should address all ethical considerations, including patient safety and informed consent.

    What is the timeline for obtaining regulatory approval from AGEMED after ethical approval?

    After receiving ethical approval, the application to AGEMED can take approximately 60-90 days for regulatory approval.

    What should researchers be prepared for during the AGEMED approval process?

    Researchers should be prepared to respond promptly to any queries or requests for additional information from AGEMED during the approval process.

    What compliance requirements must be maintained throughout the study?

    Throughout the study, researchers must adhere to all compliance requirements, including regular reporting and monitoring of study progress to ensure the integrity of the study.

    How can leveraging bioaccess’s resources assist in conducting first-in-human trials in Bolivia?

    Leveraging bioaccess’s resources can streamline the process of conducting first-in-human trials in Bolivia by providing guidance on regulatory compliance and operational efficiency.

    List of Sources

    1. Understand Regulatory Requirements for First-in-Human Trials in Bolivia
      • ftp.bills.com.au (https://ftp.bills.com.au/lunar-tips/bolivias-drug-regulatory-authority-a-comprehensive-overview-1767648693)
      • 5 Steps for Regulatory Compliance for Medtech Trials in Bolivia | bioaccess® (https://bioaccessla.com/blog/5-steps-for-regulatory-compliance-for-medtech-trials-in-bolivia)
      • pharmaboardroom.com (https://pharmaboardroom.com/legal-reports/the-pharma-legal-handbook-bolivia)
      • bioaccessla.com (https://bioaccessla.com/blog/designing-clinical-trials-for-medical-devices-in-bolivia-key-steps)
    2. Select an Appropriate CRO for Your First-in-Human Trial
      • clinicalleader.com (https://clinicalleader.com/doc/the-value-of-a-high-performing-regulatory-function-within-a-cro-0001)
      • First-in-Human Clinical Trial CRO — U.S. & Latin America | bioaccess® (https://bioaccessla.com/first-in-human-cro)
      • pharmexec.com (https://pharmexec.com/view/most-impactful-quotes-january)
      • novotech-cro.com (https://novotech-cro.com/whitepapers/precision-oncology-clinical-trials-statistics-2024)
      • A cross-sectional study on the first-in-human trials of anticancer drugs in Japan and the United States and the probability of approval – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC12474682)
    3. Design a Comprehensive Trial Protocol
      • A cross-sectional study on the first-in-human trials of anticancer drugs in Japan and the United States and the probability of approval – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC12474682)
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC7220914)
      • ourworldindata.org (https://ourworldindata.org/grapher/average-study-length-by-phase)
      • clinicalleader.com (https://clinicalleader.com/topic/clinical-trial-protocol-design-development)
    4. Implement Effective Patient Recruitment Strategies
      • Clinical Trials Patient Recruitment in Latin America | H Clinical (https://hclinical.com/patient-recruitment)
      • 10 Patient Experience Quotes for Inspiration (https://carecloud.com/continuum/patient-experience-quotes-for-inspiration)
      • 10 Inspiring Patient Experience Quotes | Relias (https://relias.com/blog/patient-experience-quotes)
      • servahealth.com (https://servahealth.com/patient-support-insights/patient-engagement-services-improving-clinical-trial-recruitment-and-retention)
      • Rate of Patient Recruitment to International Multicenter Clinical Studies in Eastern Europe Countries | Applied Clinical Trials Online (https://appliedclinicaltrialsonline.com/view/rate-of-patient-recruitment-to-international-multicenter-clinical-studies-in-eastern-europe-countries)

  • Best Practices for First in Human Trials in Brazil: Strategies for Success

    Best Practices for First in Human Trials in Brazil: Strategies for Success

    Introduction

    Brazil’s emergence as a key player in first-in-human trials presents both opportunities and challenges. Driven by a treatment-naive patient population and significant regulatory reforms, Brazil has rapidly positioned itself as a vital hub for clinical research.

    With the recent changes in Law No. 14,874/2024, the approval process has been streamlined, offering sponsors a remarkable opportunity to expedite their clinical research endeavors. However, navigating Brazil’s evolving regulatory landscape can be daunting for stakeholders.

    How can they effectively leverage Brazil’s unique advantages while overcoming the inherent challenges of patient recruitment and regulatory compliance? To succeed in early-stage clinical trials, stakeholders need to grasp these dynamics.

    Understand the Landscape of First-in-Human Trials in Brazil

    Brazil has emerged as a pivotal hub for first in human trial Brazil research, fueled by its diverse and treatment-naive patient population. The recent enactment of Law No. 14,874/2024 has reshaped the regulatory landscape significantly, reducing approval timelines from an average of 265 days to just 90 days. This reform simplifies the process. It also enhances the country’s appeal for first in human trial Brazil. Consequently, sponsors can expedite their research and development initiatives.

    The Brazilian regulatory body, ANVISA, plays a crucial role in supervising research studies, ensuring that they conform to international benchmarks such as ICH-GCP. This compliance is key to producing data that meets FDA and EMA standards, which is vital for attracting investment and facilitating market entry. Moreover, the incorporation of ethical review processes under the new regulations enhances efficiency and participant safety, bolstering the region’s status as a competitive force in the global research landscape.

    Grasping these dynamics is crucial for stakeholders aiming to leverage Latin America’s strategic benefits in early-stage research, particularly in the context of first in human trial Brazil. The integration of accelerated timelines, a strong regulatory system, and a diverse patient population establishes this nation as an ideal selection for early-stage clinical evaluations in the MedTech and Biopharma industries.

    This flowchart illustrates the key components of first-in-human trials in Brazil. Start at the top with the main topic, then follow the arrows to see how regulatory changes, the role of ANVISA, and benefits for stakeholders are interconnected. Each section highlights important aspects that contribute to Brazil's position in early-stage clinical research.

    Successfully conducting first-in-human (FIH) studies hinges on a thorough understanding of the regulatory framework in this region. The first step is to submit a Clinical Trial Application (CTA) to ANVISA. This application must include a comprehensive Drug Clinical Development Dossier (DDCM), which consists of the study protocol, informed consent forms, and investigator qualifications. ANVISA is required to provide a written opinion within 45 calendar days, followed by a final decision within a maximum of 90 working days. Following ICH-GCP guidelines helps ensure that the approval process goes smoothly. Additionally, obtaining approval from local ethics committees (CEPs) is mandatory, as their endorsement is a prerequisite for ANVISA’s review. Understanding these regulatory requirements and timelines allows sponsors to prepare their submissions efficiently. This reduces the risk of delays that could hinder study initiation. The nation’s efficient procedures and dedication to regulatory adherence establish it as a key site for first in human trial Brazil, offering notable benefits in speed and cost-effectiveness. Understanding these processes not only streamlines approvals but also positions the nation as a premier destination for clinical research.

    This flowchart outlines the steps needed to navigate regulatory requirements for clinical trials. Start with submitting your application, then follow the arrows to see what documents you need and the timelines for ANVISA's review and final decision. Don't forget to get approval from local ethics committees!

    Implement Efficient Strategies for Accelerated Trial Execution

    To accelerate trial execution in Latin America, sponsors must leverage the region’s unique advantages. Collaborating with established contract research organizations (CROs) is essential, as these partnerships provide invaluable insights into the local landscape. This collaboration enables quicker recruitment of participants and site selection. Local CROs excel at navigating Brazil’s regulatory environment, particularly with ANVISA, where approval timelines average 215 days – significantly longer than in many other regions. Working with these organizations allows sponsors to streamline submissions to ANVISA and CONEP. This ensures compliance with ICH-GCP standards and speeds up the approval process.

    Furthermore, using technology for data management and monitoring can really boost operational efficiency. It enables real-time adjustments and enhances data integrity. Implementing adaptive design approaches allows for flexibility in response to interim results, potentially reducing the overall duration of the study. Conducting comprehensive feasibility evaluations before study initiation can uncover potential obstacles and enhance the recruitment process. It’s important to note that 40% of clinical studies in Brazil fail due to low participant enrollment. This issue can be alleviated through improved education and awareness strategies, which local CROs can assist in implementing.

    By concentrating on these strategies, sponsors can significantly shorten timelines and lower costs, making their studies more competitive in the global landscape. The incorporation of local knowledge not only improves research efficiency but also establishes the region as a strategic center for early-stage studies. This leverages its diverse demographic and enhances access to treatment-naive groups. Utilizing insights from bioaccess’s Global Trial Accelerators™ can further enable MedTech and Biopharma innovators to effectively navigate the complexities of clinical studies in Latin America. By embracing these strategies, sponsors not only enhance their competitiveness but also position Latin America as a pivotal hub for clinical research.

    This flowchart outlines the key strategies for speeding up clinical trials in Latin America. Each box represents a strategy, and the arrows show how they connect to improve trial execution. Follow the flow to see how each step contributes to a more efficient process.

    Enhance Patient Recruitment and Engagement Strategies

    Recruiting and engaging participants effectively is a pivotal factor in the success of first in human trial Brazil. To build trust within local communities, sponsors should work closely with healthcare providers and advocacy groups. Engaging local stakeholders not only enhances credibility but also facilitates smoother recruitment processes. Digital platforms can greatly enhance visibility and accessibility. This is especially true for younger populations who engage more with online content.

    Tailoring recruitment messages to reflect cultural nuances and addressing potential barriers – such as language differences – can lead to higher enrollment rates. For instance, 24.1% of physicians observed a lack of research awareness among the population as a barrier to recruitment, emphasizing the necessity for targeted educational initiatives. Offering clear, accessible information about the research process and its potential advantages enables individuals to make informed choices regarding participation.

    Additionally, the Brazilian research environment offers distinct benefits, such as quicker enrollment of participants and reduced expenses compared to conventional markets. With regulatory organizations like ANVISA optimizing approval procedures, sponsors can anticipate faster timelines for commencing studies. In fact, the Brazilian medical research participant recruitment services market is projected to reach USD 144.4 million by 2033, reflecting a strong demand for recruitment services. By addressing obstacles such as prolonged approval durations – many sponsors struggle with lengthy approval processes, which can delay recruitment efforts – and the limited number of accessible studies, sponsors can improve patient involvement and ensure a consistent influx of participants throughout the research, ultimately aiding the success of their medical research initiatives.

    As one client pointed out, ‘Collaborating with bioaccess® enabled us to navigate the complexities of the Brazilian regulatory landscape efficiently, resulting in a successful launch ahead of schedule.’ This shows just how crucial it is to tap into local expertise and insights for better recruitment strategies. Bioaccess® is dedicated to leveraging these advantages, providing essential insights and strategies to accelerate clinical trials and market entry for MedTech and Biopharma companies in Latin America.

    The central idea is about enhancing recruitment strategies. Each branch represents a key area of focus, and the sub-branches provide specific actions or insights related to that area. This layout helps visualize how different strategies connect and contribute to the overall goal.

    Conclusion

    Brazil’s regulatory landscape presents both opportunities and challenges for first-in-human (FIH) trials, making it essential for sponsors to navigate it wisely. The recent regulatory reforms, particularly Law No. 14,874/2024, have significantly reduced approval timelines, making it an attractive option for sponsors looking to expedite their research and development processes. By capitalizing on Brazil’s unique advantages, stakeholders can enhance their clinical trial success rates while addressing the complexities of the local landscape.

    Let’s explore some best practices that can make FIH trials in Brazil successful. Key strategies include:

    • Collaborating with experienced contract research organizations (CROs) to facilitate smoother regulatory submissions and participant recruitment.
    • Prioritizing compliance with ANVISA and ICH-GCP guidelines to ensure studies meet international standards, which is vital for attracting investment.
    • Implementing targeted patient engagement strategies to significantly improve recruitment rates, addressing common barriers and enhancing overall trial efficiency.

    In conclusion, Brazil’s evolving regulatory environment and its commitment to fostering a conducive research atmosphere position it as a strategic hub for early-stage clinical trials. By adopting the outlined best practices, sponsors can not only capitalize on the country’s advantages of speed and cost-effectiveness but also contribute to the advancement of medical research in Latin America. By embracing these strategies, sponsors not only enhance their trial outcomes but also play a pivotal role in shaping the future of healthcare in Latin America.

    Frequently Asked Questions

    What recent changes have impacted first-in-human trials in Brazil?

    The enactment of Law No. 14,874/2024 has significantly reshaped the regulatory landscape for first-in-human trials in Brazil, reducing approval timelines from an average of 265 days to just 90 days.

    How does Brazil’s patient population benefit first-in-human trials?

    Brazil’s diverse and treatment-naive patient population provides a valuable resource for researchers conducting first-in-human trials, enhancing patient recruitment and the overall quality of clinical evaluations.

    What role does ANVISA play in first-in-human trials in Brazil?

    ANVISA, the Brazilian regulatory body, supervises research studies to ensure they conform to international standards such as ICH-GCP, which is essential for producing data that meets FDA and EMA standards.

    What are the compliance requirements for conducting first-in-human trials in Brazil?

    Compliance with international benchmarks like ICH-GCP is required, ensuring that research adheres to ethical standards and produces reliable data for market entry.

    How does the new regulation enhance participant safety in clinical trials?

    The incorporation of ethical review processes under the new regulations improves efficiency and participant safety, which is crucial for maintaining trust and integrity in clinical research.

    Why is Brazil considered a competitive force in the global research landscape?

    Brazil’s accelerated approval timelines, strong regulatory system, and diverse patient population establish it as an ideal location for early-stage clinical evaluations in the MedTech and Biopharma industries.

    What strategic advantages does Latin America offer for early-stage clinical trials?

    Latin America, particularly Brazil, offers speed in approval processes, cost efficiency, and effective patient recruitment, making it a strategic advantage for conducting early-stage clinical trials.

    List of Sources

    1. Understand the Landscape of First-in-Human Trials in Brazil
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/brazil)
      • lickslegal.com (https://lickslegal.com/post/new-regulations-for-clinical-research-in-brazil)
      • statista.com (https://statista.com/statistics/1067453/brazil-number-clinical-trials-initiated?srsltid=AfmBOorNeHMRYCS3WQDds59a6Iv28RyooIach1XHknXX6qQftk0GdNwp)
      • lexology.com (https://lexology.com/library/detail.aspx?g=b1b655f4-963a-4be7-876c-81afb05caef6)
    2. Navigate Regulatory Requirements for Clinical Trials
      • lickslegal.com (https://lickslegal.com/post/new-regulations-for-clinical-research-in-brazil)
      • credevo.com (https://credevo.com/articles/2019/03/14/clinical-trial-regulatory-process-brazil)
      • linkedin.com (https://linkedin.com/posts/cristiane-salles-36bbb336_clinicalresearch-brazil-clinicaltrials-activity-7434614266575560704-Kn4L)
      • linkedin.com (https://linkedin.com/posts/bioaccess_clinicaltrials-brazil-anvisa-activity-7447976698958106627-98MW)
      • bioaccessla.com (https://bioaccessla.com/blog/brazil-anvisa-parallel-review-clinical-trial-approvals-2026)
    3. Implement Efficient Strategies for Accelerated Trial Execution
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC10898894)
      • pharmaphorum.com (https://pharmaphorum.com/views-and-analysis/accelerating-clinical-research-brazil)
      • lek.com (https://lek.com/insights/life-sciences-pharma/unlocking-brazils-clinical-trial-opportunity-strategic-roadmap)
    4. Enhance Patient Recruitment and Engagement Strategies
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC10898894)
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trial-patient-recruitment-services-market/brazil)
      • statista.com (https://statista.com/statistics/1067453/brazil-number-clinical-trials-initiated?srsltid=AfmBOopZcK_QgUFOSPSk-AkVnIixO9riFznsGp0hqgHHsDLIMGY9VpCC)

  • Julio Martinez-Clark on Tech Can't Save Us: Accelerating MedTech and First-in-Human Success

    Julio Martinez-Clark on Tech Can’t Save Us: Accelerating MedTech and First-in-Human Success

    Julio Martinez-Clark, co-founder and CEO of bioaccess®, recently joined host Paul David on Tech Can’t Save Us — the podcast by Literal Humans that explores technology’s real-world limits and what it takes to build companies that last. The episode is now live across all major podcast platforms.

    Listen on Apple Podcasts | Listen on Spotify | Full episode on the TCSU website

    The “Valley of Death” — And How MedTech Startups Survive It

    The conversation opens with a sobering reality: roughly 90% of healthcare startups fail — not because their technology is flawed, but because they exhaust their capital before generating the clinical data needed to raise their next round or secure an exit.

    With monthly burn rates averaging $300,000 to $400,000, the clock is always running. The fastest path off the clock is the fastest path to first-in-human data.

    That’s the problem bioaccess® was purpose-built to solve.

    What bioaccess® Does — and Why LATAM

    bioaccess® is the world’s first contract research organization (CRO) built specifically around first-in-human (FIH) clinical trials. By combining deep site relationships, regulatory expertise, and operational infrastructure across Latin American markets — including Panama and El Salvador — bioaccess® compresses clinical timelines by up to 40%.

    As Julio explained on the podcast, speed in LATAM doesn’t mean cutting corners. Every trial bioaccess® runs adheres strictly to ICH and GCP guidelines — the same international standards required by the FDA and EMA. What differs is execution: rapid site activation, predictable patient recruitment, and a team that has done this before, in these markets, for these device types.

    Democratizing Access to Life-Saving Innovation

    One of the most compelling threads in the conversation is the human dimension of clinical research. The patients who participate in first-in-human trials in lower-income settings often have no other access to advanced medical care. For them, participation isn’t a transaction — it’s a lifeline.

    Julio discussed how this dynamic shapes bioaccess®’s philosophy: that moving faster on clinical timelines is not just a business imperative but a moral one. Compassionate, high-quality clinical research restores dignity and delivers access to innovations that would otherwise take years longer to reach these communities.

    Building Without Outside Capital

    The episode also covers bioaccess®’s self-funded growth strategy — a deliberate choice that has kept the company focused on delivering value to sponsors rather than chasing metrics that serve investors. Julio shares the discipline required to grow this way and the common mistakes he sees first-time founders make when they let fundraising urgency drive clinical decision-making.

    La Cebolla de Pandora

    Julio reflects on the period he spent writing La Cebolla de Pandora — a book that gave him the space to examine his own assumptions about what success, purpose, and impact actually mean in the context of a company trying to change how medicine reaches people.

    Listen Now

    The full episode runs 26 minutes. You can find it on the Tech Can’t Save Us website, Apple Podcasts, Spotify, and all major platforms.

    If you’re a MedTech or biopharma startup navigating your path to first-in-human data, explore how bioaccess® can compress your timeline →

    Tech Can’t Save Us is produced by Literal Humans, a marketing agency focused on technology and innovation.